Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Europe’s BeNeLuxA Coalition Moving Too Fast?

Executive Summary

The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.

You may also be interested in...



The BeNeLuxA Medicines Access Coalition: Resetting The Balance of Power in Europe?

The BeNeLuxA coalition shows that “resetting the balance of power” is possible to give governments more clout in pricing negotiations, says the European Public Health Alliance.

Is Dutch Govt Pursuing Wider EU Discussion And Collaboration On Pricing and Reimbursement?

An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.

What EU Governments Need To Do About Access To Affordable Medicines

In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS121544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel